Ali Farzad, Laurin Marie-Yseult, Larivière Christine, Tremblay Denis, Cloutier Denise
Outcomes Research, Pfizer Canada Inc., 17300 Trans-Canada Highway, Kirkland, Quebec H9J 2M5, Canada.
Can J Clin Pharmacol. 2003 Fall;10(3):101-6.
Dyslipidemias are a modifiable risk factor for coronary heart disease. The benefits of cholesterol reduction drug therapies are limited by poor patient compliance with drug regimens.
To determine the impact of a community pharmacist pilot disease-management program on patient compliance with lipid-lowering drug therapy and on serum cholesterol levels.
One hundred forty-nine patients who were nonadherent to prescribed hypolipidemic drug regimens were recruited for this six-month prospective study. Each subject served as their own control. Pharmacists educated these patients on lipid disorders, the benefit of medication compliance and lifestyle modifications that reduce the risk for coronary heart disease. Pharmacists followed up participants by telephone at two-month intervals. Drug renewal rates were monitored throughout the study and plasma lipid levels were measured at study outset and study end.
Pharmacist intervention and patient-education programs significantly increased medication compliance, as shown by a 15.3% increase (P<0.05) in the number of compliant patients and an 11 day (P<0.001) reduction in the average number of days to prescription renewal. Concurrently, levels of total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol, were reduced by 6%, 16.2%, and 8.5% (P<0.001, 0.01, 0.01), respectively. High density lipoprotein (HDL) cholesterol remained relatively unchanged (+0.7%) so that the LDL to HDL ratio was improved by 17.2% overall (P<0.01). Almost all of the patients (99.2%) were satisfied with the program and expressed a willingness to pay an average $34.50 per 30 min consultation for the pharmacist services offered.
Pharmacists can contribute significantly to disease management of dyslipidemic individuals.
血脂异常是冠心病的一个可改变的风险因素。降胆固醇药物治疗的益处因患者对药物治疗方案的依从性差而受到限制。
确定社区药剂师试点疾病管理项目对患者降脂药物治疗依从性和血清胆固醇水平的影响。
招募了149名未遵守规定降脂药物治疗方案的患者进行这项为期6个月的前瞻性研究。每个受试者作为自己的对照。药剂师就脂质紊乱、药物依从性的益处以及降低冠心病风险的生活方式改变对这些患者进行教育。药剂师每两个月通过电话对参与者进行随访。在整个研究过程中监测药物续方率,并在研究开始和结束时测量血浆脂质水平。
药剂师干预和患者教育项目显著提高了药物依从性,依从患者数量增加了15.3%(P<0.05),处方续方平均天数减少了11天(P<0.001)。同时,总胆固醇、甘油三酯和低密度脂蛋白(LDL)胆固醇水平分别降低了6%、16.2%和8.5%(P<0.001、0.01、0.01)。高密度脂蛋白(HDL)胆固醇保持相对不变(+0.7%),因此LDL与HDL的比率总体提高了17.2%(P<0.01)。几乎所有患者(99.2%)对该项目感到满意,并表示愿意为所提供的药剂师服务每30分钟咨询支付平均34.50美元。
药剂师可为血脂异常个体的疾病管理做出重大贡献。